Literature DB >> 15061250

Sex, ethnicity, and antipsychotic medication use in patients with psychosis.

Lesley M Arnold1, Stephen M Strakowski, Michael L Schwiers, Jennifer Amicone, David E Fleck, Kimberly B Corey, Jenni E Farrow.   

Abstract

Previous studies suggested that African American patients with psychotic disorders receive higher doses of antipsychotic medication than white patients, are more likely to receive depot antipsychotics, and are less likely to be prescribed second-generation antipsychotics. African-American men in particular may be most likely to receive excessive doses of antipsychotics and depot antipsychotics, although this is less clear. Few studies have examined how sex and ethnicity interactions affect treatment of psychotic disorders. In this study, we examined whether the interaction of sex and ethnicity predicted the use of depot antipsychotics and the dosing of antipsychotics in a sample of inpatients with psychotic disorders. The inpatient records of 167 patients with psychotic disorders were evaluated for type and dose of medication at discharge. African-American men received depot antipsychotic medication more frequently than African-American women and white patients. This difference persisted after controlling for sociodemographic and clinical variables. African-American men and women with psychotic mood disorders were also more likely to be discharged on high antipsychotic doses compared with white patients. There were no ethnic or sex differences in the dosing of antipsychotics for the treatment of schizophrenia spectrum disorders. There were also no ethnic or sex differences in the use of second-generation antipsychotics.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15061250     DOI: 10.1016/S0920-9964(03)00102-6

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  16 in total

1.  Use of depot antipsychotic medications for medication nonadherence in schizophrenia.

Authors:  Joyce C West; Steven C Marcus; Joshua Wilk; Lisa M Countis; Darrel A Regier; Mark Olfson
Journal:  Schizophr Bull       Date:  2007-12-18       Impact factor: 9.306

2.  Does race affect prescribing for acute psychosis? Evaluation by a case vignette.

Authors:  Anne Connolly; David Taylor
Journal:  Ther Adv Psychopharmacol       Date:  2016-03-18

3.  Longitudinal treatment outcome of African American and Caucasian patients with first episode psychosis.

Authors:  Huijun Li; Shaun M Eack; Debra M Montrose; Jean M Miewald; Matcheri Keshavan
Journal:  Asian J Psychiatr       Date:  2011-10-12

4.  Prescription of psychiatric medications and polypharmacy in the LAMS cohort.

Authors:  Robert A Kowatch; Eric A Youngstrom; Sarah Horwitz; Christine Demeter; Mary A Fristad; Boris Birmaher; David Axelson; Neal Ryan; Thomas W Frazier; L Eugene Arnold; Andrea S Young; Marykay Gill; Robert L Findling
Journal:  Psychiatr Serv       Date:  2013-10       Impact factor: 3.084

5.  Indications for and use of long-acting injectable antipsychotics: consideration from an inpatient setting.

Authors:  Taishiro Kishimoto; Sohag Sanghani; Mark J Russ; Akeem N Marsh; Joshua Morris; Suparna Basu; Majnu John; John M Kane
Journal:  Int Clin Psychopharmacol       Date:  2017-05       Impact factor: 1.659

6.  No evidence for restrictive care practices in Măori admitted to a New Zealand psychiatric inpatient unit: do specialist cultural teams have a role?

Authors:  Shailesh Kumar; Bradley Ng; Alexander Simpson; Jesse Fischer; Elizabeth Robinson
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2008-05       Impact factor: 4.328

7.  Duration of pharmacotherapy with long-acting injectable risperidone in the treatment of schizophrenia.

Authors:  Somaia Mohamed; Robert Rosenheck; Ilan Harpaz-Rotem; Douglas Leslie; Michael J Sernyak
Journal:  Psychiatr Q       Date:  2009-09-19

Review 8.  Pediatric bipolar disorder: validity, phenomenology, and recommendations for diagnosis.

Authors:  Eric A Youngstrom; Boris Birmaher; Robert L Findling
Journal:  Bipolar Disord       Date:  2008-02       Impact factor: 6.744

9.  Race and long-acting antipsychotic prescription at a community mental health center: a retrospective chart review.

Authors:  Neil Krishan Aggarwal; Robert A Rosenheck; Scott W Woods; Michael J Sernyak
Journal:  J Clin Psychiatry       Date:  2012-04       Impact factor: 4.384

10.  Treatment of schizophrenia with long-acting fluphenazine, haloperidol, or risperidone.

Authors:  Mark Olfson; Steven C Marcus; Haya Ascher-Svanum
Journal:  Schizophr Bull       Date:  2007-04-29       Impact factor: 9.306

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.